Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$5.67 - $8.06 $15,876 - $22,568
-2,800 Reduced 84.85%
500 $3,000
Q1 2024

May 15, 2024

SELL
$6.63 - $10.69 $663 - $1,069
-100 Reduced 2.94%
3,300 $26,000
Q4 2023

Feb 14, 2024

BUY
$3.61 - $7.76 $3,610 - $7,760
1,000 Added 41.67%
3,400 $23,000
Q3 2023

Nov 14, 2023

BUY
$4.68 - $9.26 $3,744 - $7,408
800 Added 50.0%
2,400 $12,000
Q2 2023

Aug 14, 2023

SELL
$8.5 - $10.38 $7,650 - $9,342
-900 Reduced 36.0%
1,600 $14,000
Q1 2023

May 15, 2023

SELL
$7.53 - $10.95 $69,276 - $100,740
-9,200 Reduced 78.63%
2,500 $23,000
Q4 2022

Feb 14, 2023

BUY
$9.44 - $13.09 $3,776 - $5,236
400 Added 3.54%
11,700 $116,000
Q3 2022

Nov 14, 2022

BUY
$8.14 - $12.25 $91,982 - $138,425
11,300 New
11,300 $135,000

Others Institutions Holding AXGN

About Axogen, Inc.


  • Ticker AXGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 42,283,700
  • Market Cap $648M
  • Description
  • AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
More about AXGN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.